Management of renal cell carcinoma Journal Article


Authors: Wolchok, J. D.; Motzer, R. J.
Article Title: Management of renal cell carcinoma
Abstract: Surgical resection remains the cornerstone of management for localized renal cell carcinoma. No effective postsurgical adjuvant therapy has been established for patients with locally advanced disease who are at high risk for recurrence. The effective treatment of metastatic kidney cancer remains a challenge. Immunologic therapy with cytokines, such as interferon-alfa (Intron A, Roferon-A) and interleukin-2 (IL-2 [Proleukin]), benefit relatively small numbers of patients. Preclinical research and clinical investigations aimed at identifying new agents and treatment programs with improved antitumor activity against metastases remain the highest priorities in this refractory disease. New immunologic approaches to the treatment of both advanced and high-risk postsurgical disease are focusing on novel vaccine therapies to target both renal epithelial and vascular antigens.
Keywords: metastasis; kidney carcinoma; kidney neoplasms; monoclonal antibody; cytokine; cytokines; antibodies, monoclonal; cancer vaccine; kidney tumor; cancer vaccines; carcinoma, renal cell; humans; human; article
Journal Title: Oncology (Norwalk)
Volume: 14
Issue: 1
ISSN: 0890-9091
Publisher: C M P Medica LLC * The Oncology Group  
Date Published: 2000-01-01
Start Page: 29
End Page: 32, 34
Language: English
PUBMED: 10680148
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Citation Impact
MSK Authors
  1. Robert Motzer
    1243 Motzer
  2. Jedd D Wolchok
    905 Wolchok